Skip to main content
Clinical Trials/DRKS00017043
DRKS00017043
Recruiting
N/A

Potential influence of coagulation inhibitionon the perception of fear or aggressiveness

niversitätsklinik für Kardiologie und Angiologie0 sites25 target enrollmentMarch 28, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
I48
Sponsor
niversitätsklinik für Kardiologie und Angiologie
Enrollment
25
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 28, 2019
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversitätsklinik für Kardiologie und Angiologie

Eligibility Criteria

Inclusion Criteria

  • Treatment group: Patients receiving dabigatran under one of the approved indications, e.g. non\-valvular atrial fibrillation, thrombosis, pulmonary embolism or control group: Patients who, after clarifying questionable cardiac arrhythmias, do not require further drug or pacemaker treatment

Exclusion Criteria

  • a) contraindications for dabigatran, e.g. Hypersensitivity to the active substance or to any of the excipients, severe renal insufficiency (creatinine clearance \[CrCl] \<30 ml / min), acute clinically relevant bleeding, organ damage increasing the risk of bleeding, spontaneous or pharmacological limitation of haemostasis, severe liver disease, concomitant systemically administered ketoconazole, cyclosporin, itraconazole or tacrolimus; Pat. With artificial heart valves.
  • b) Severe infections, trauma, tumors or terminal diseases that affect the brain.
  • c) Lack of consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials